The Association of Anticoagulation Intensity with Outcomes in Hospitalized COVID-19 Patients
Table 1
Subject characteristics.
Characteristic
Total (n = 915)
Standard-dose prophylaxis (n = 813)
High-dose prophylaxis (n = 32)
Therapeutic anticoagulation (n = 70)
value
Age (yrs)
58 (45–70)
58 (45–69)
62 (51–70)
65.5 (58–77)
<0.0001
Female n (%)
416 (45.5)
378 (46.5)
11 (34.4)
27 (38.6)
0.1948
BMI (kg/m2)†
29.1 (24.9–34)
29.2 (24.9–34)
27.1 (24.9–30.9)
28.7 (23.3–35.2)
0.6809
Race
0.0072
Black, n (%)
421 (46)
364 (44.8)
14 (43.8)
43 (61.4)
White, n (%)
153 (16.7)
130 (16)
8 (25)
15 (21.4)
Other, n (%)
151 (16.5)
142 (17.5)
6 (18.8)
3 (4.3)
Unknown, n (%)
190 (20.8)
177 (21.8)
4 (12.5)
9 (12.9)
Comorbidities
Current tobacco use, n (%)
117 (12.8)
105 (12.9)
5 (15.6)
7 (10)
0.6816
Current alcohol use, n (%)
187 (20.4)
170 (20.9)
10 (31.3)
7 (10)
0.0225
Diabetes mellitus, n (%)
323 (35.3)
285 (35.1)
12 (37.5)
26 (37.1)
0.8839
Hypertension, n (%)
547 (59.8)
478 (58.8)
18 (56.3)
51 (72.9)
0.0590
Prior history of venous thromboembolism, n (%)
55 (6)
34 (4.2)
4 (12.5)
17 (24.3)
<0.0001
Prior medication use
Anticoagulants, n (%)
70 (7.7)
24 (3)
4 (12.5)
42 (60)
<0.0001
Antiplatelet agents, n (%)
216 (23.6)
188 (23.1)
7 (21.9)
21 (30)
0.4111
Inflammatory markers
Initial D-dimer (ng/mL)†
317 (189–603)
310 (185–547)
2346.5 (601–3360.5)
357.5 (208–834)
<0.0001
Initial CRP (mg/L)†
65.6 (24.9–127.5)
65.6 (24.6–124.6)
84.9 (26.6–153.3)
64.9 (28.1–125.7)
0.3570
In-hospital thrombosis
Venous thromboembolism, n (%)
45 (4.9)
29 (3.6)
2 (6.3)
14 (20)
<0.0001
Data are median (25th–75th percentile) for age, BMI, initial D-dimer, and initial CRP. All other variables are n (%) where n is the total number of patients. values comparing all three anticoagulation groups are from Fisher’s exact test or Kruskal–Wallis test. †There are fewer n for the prophylactic group in that variable. For BMI, n = 811; for initial D-dimer, n = 786; for CRP, n = 797 for the prophylactic group.
